Vi vill rikta ett tack till Britt-Marie Linnarsson, Kemist, Minna Bernhardsson, Leg Biomedicinsk analytiker, Evelina Albertsson, Leg Biomedicinsk analytiker och övrig personalen vid laboratoriemedicin på Länssjukhuset Ryhov i Region Jönköpings län som har visat stöd och handlett oss genom den laborativa verifieringen. Vi vill även tacka Institutet för medicinsk genetik i Dresden för deras bidrag av prover och analysresultat till vår överensstämmelsejämförelse. Slutligen vill vi tacka Peter Esbjörnsson från Thermo Fisher Scientific och Lena Gottnersson från Perkin Elmer för hjälpsam information samt Jan Strindhall, Lektor för den vetenskapliga vägledningen i arbetet.
Referenser
1. Say L, Chou D, Gemmill A, Tunçalp Ö, Moller AB, Daniels J, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Global Health. 2014; 2:323–33. 2. Maternal mortality: fact sheet n°348. Genève: World Health Organisation; 2015 [2016
mars 29]
Tillgänglig via: http://www.who.int/en/
3. Hernández-Díaz S, Toh S, Cnattingius S. Risk of pre-eclampsia in first and subsequent pregnancies: prospective cohort study. British Medical Journal (BMJ).
2009;338:b2255.
4. Harlow F, Brown M. The diversity of diagnoses of preeclampsia. Hypertension in Pregnancy. 2001; 20(1):57-67.
5. Roberts JM, Cooper DW. Pathogenesis and genetics of pre-eclampsia. The Lancet. 2001;357(9249):53-56.
6. Roberts JM, Hubel CA. The two stage model of preeclampsia: variations on the theme. Placenta. 2009;30(A):32-37.
7. Geary M. The HELLP syndrome. A International Journal of Obstetrics and Gynaecology (BJOG). 1997(104):887-891.
8. Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S et al. Prevention of preeclampsia and intrauterine growth restriction with Aspirin started in early pregnancy: a meta-analysis. The American Journal Obstetrics and Gynaecology (AJOG). 2010;116(2):402-414.
9. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet. 2005;365:785-99.
10. Meis PJ, Goldenberg RL, Mercer BM, Iams JD, Moawad AH, Miodovnik M et al. The preterm prediction study: risk factors for indicated preterm births. AJOG.
1998;178(3):562-567.
11. Milne F, Redman C, Walker J, Baker P, Bradley J, Cooper C et al. The pre-eclampsia community guideline (PRECOG): how to screen for and detect onset of pre-eclampsia in the community. BMJ. 2005;330:576-580.
12. Nahid S, Khadije YM. The study of diagnostic value of placental growth factor for prediciting pre-eclampsia in the first trimester of pregnancy. Global Journal of Surgery. 2014;2(1):12-15.
13. Maglione D, Guerriero V, Vigleitto G, Delli-Bovi P, Persico MG. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Biochemistry. 1991;88:9267-9271.
14. Athanassiades A, Lala PK. Role of placenta growth factor (PlGF) in human extravillous trophoblast proliferation, migration and invasiveness. Placenta 1998;19:465-473.
15. Zygmunt M, Herr F, Munstedt K, Lang U, Liang OD. Angiogenesis and vasculogenesis in pregnancy. Reproductive Biology. 2003;110:10-18.
16. Riabatti D. The discovery of the placental growth factor and its role in angiogenesis; a historical review. Angiogenesis. 2008;11:215-221.
17. Maglione D, Guerriero V, Viglietto G, Ferraro MG, Aprelikova O, Alitalo K et al. Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PlGF), are transcribed from a single gene of chromosome 14. Oncogene.
1993;8(4):925-931.
18. Cao Y, Ji WR, Qi P, Rosin Å, Cao Y. Placenta growth factor: Identification and characterization of a novel isoform generated by RNA alternative splicing. Biochemical and Biophysical Research Communications. 1997;235(3):493-498. 19. Yang W, Ahn H, Hinrichs M, Torry RJ, Torry DS. Evidence of a novel isoform of
placenta growth factor (PlGF-4) expressed in human trophoblast and endothelial cells. Journal of Reproductive Immunology.2002;60(1):53-60.
20. De Falco S. The discovery of placenta growth factor and its biological activity. Experimental and Molecular Medicine. 2012;44(1):1-9.
21. Bates DO. An unexpected tail of VEGF and PlGF in pre-eclampsia. Biochemical Society Transactions. 2011;39(6):1576–1582.
22. Nucci M, Poon LC, Demirdjian G, Darbouret B, Nicolaides KH. Maternal serum placental growth factor (PlGF) isoforms 1 and 2 at 11-13 weeks' gestation in normal and pathological pregnancies. Fetal Diagnosis and Therapy. 2014;36:106-116. 23. Vägledning vid ackreditering av certifieringsorgan och certifiering med hänvisning
till: STEMFS 2014:2 Statens energimyndighets föreskrifter om energikartläggning i stora företag. Borås: Styrelsen för ackreditering och teknisk kontroll (SWEDAC); 2015 [2016 maj 20]
24. Instructions for use: BRAHMS PlGF plus KRYPTOR. Hennigsdorf: Thermo Fisher Scientific; 2015 [2016 mars 16]
Tillgänglig via: http://www.brahms-instruments.com/
25. TRACE technology (Time Resolved Amplified Cryptate Emission). http://cezanne.fr/en/technology-34200-2.php [2016 maj 16]
26. The Nobel Prize in Chemistry 1987; Press Release. Stockholm: Kungliga vetenskapsakademin; 1987 [2016 maj 16]
Tillgänglig via: http://www.nobelprize.org
27. Bruksanvisning: BRAHMS KRYPTOR compact consumables. Hennigsdorf: Thermo Fisher Scientific; 2015 [2016 mars 16]
Tillgänglig via: http://www.brahms-instruments.com/
28. Bruksanvisning: BRAHMS Free βhCG KRYPTOR. Hennigsdorf: Thermo Fisher Scientific; 2015 [2016 mars 16]
Tillgänglig via: http://www.brahms-instruments.com/
29. Martin RF. General Deming regression for estimating systematic bias and its confidence interval in method-comparison studies. Clinical Chemistry; 2000;46(1):100-104.
30. Giavarina D. Understanding Bland Altman analysis. Biochemia medica. 2015;25(2):141-151.
31. Lag om etikprövning av forskning som avser människor (SFS 2003:406) 4 §. Stockholm: Justitiedepartementet.
32. Quantikine ELISA: Human PlGF Immunoassay. Minneapolis, USA: R&D Systems. Inc. 2015 [2016 april 11]
Tillgänglig via: https://www.rndsystems.com/
33. PlGF: Human placentar tillväxtfaktor. Mannheim, Tyskland: Roche Diagnostics. 2015 [2016 april 11]
Tillgänglig via: http://www.roche.se/
34. Lu Y, Young J, Meng G. Electrochemiluminescence to detect surface proteins on live cells. Current opinion in Pharmacology. 2007; 7: 541–546.
35. Delfia Xpress PlGF 1-2-3 Time-resolved fluoroimmunoassay: Instructions for use. Turku, Finland. Perkin Elmer Inc: 2014 [2016 april 22]
36. Applications of time-resolved fluorometry with the DELFIA method. Turku, Finland. Perkin Elmer: 2002 [2016 april 22]
Tillgänglig via: http://www.perkinelmer.com
37. Instructions for use: PlGF ELISA (human placenta growth factor). Marburg, Tyskland. DRG Instruments: 2016 [2016 april 11]
Tillgänglig via: http://www.drg-diagnostics.de
38. Akolekar R, de Cruz J, Foidart JM, Munaut C, Nicolaides KH. Maternal plasma soluble fms-like tyrosine kinase-1 and free vascular endothelial growth factor at 11 to 13 weeks of gestation in preeclampsia. Prenatal Diagnostics. 2010;30(3):191–7. 39. Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of
preeclampsia. The New England Journal of Medicine. 2004; 350:672–683.
40. Patterson W, Werness P, Payne WJ, Matsson P, Leflar C, Melander T et al. Random and Continuous-Access Immunoassays with Chemiluminescent Detection by Access® Automated Analyzer. Clinical Chemistry. 1994;40(11):2042-2045
41. Hnasko R, editor. Elisa: methods and protocols. 2015. p. 8-9, 52.
42. Bjørkholt Andersen L, Frederiksen-Møller B, Work Havelund K, Dechend R, Stener Jørgensen J, Jensen BL et al. Diagnosis of preeclampsia with soluble Fms–like tyrosine kinase 1/placental growth factor ratio: an inter–assay comparison. Journal of the American Society of Hypertension. 2015;9(2): 86–96.
43. Agger R. Immunologi. 1. uppl. Lund: Studentlitteratur; 2006. s. 152
44. Cowans NJ, Kisanga M, Khan A, Spencer K. A comparison of two immunoassay methods for the mesurement of maternal serum placental growth factor in early pregnancy. Fetal Diagnosis and Therapy. 2012;31:254-259.
Gäller för
Medicinsk diagnostik Laboratoriemedicin länsgem